Drug intelligence / Profile preview

VYR-302

Development stage: Preclinical
Lead developer: Vyripharm International
Modality: Small Molecules

Overview

VYR-302 is a preclinical-stage small molecule therapeutic being developed by Vyripharm International. It is designed to target the serotonin system for the treatment of mood disorders. The drug is part of Vyripharm's broader effort to develop precision medicines that integrate diagnostic imaging with targeted therapies. Currently in the preclinical phase, VYR-302 aims to provide a more tailored approach to managing psychiatric conditions by modulating serotonergic signaling.

Targets

5-HT (Serotonin receptors)

Beyond the preview

Go deeper on VYR-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-302.

Explore the full profile